Hospital Clinic De Barcelona

Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron

Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Fundación Solti

Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron

Aleix Prat Aparicio

Antonio Llombart Cussac

Javier Cortés Castán

The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.

Growing community of inventors

Barcelona, Spain

Aleix Prat Aparicio